“…also supposed that MSCs-EVs should be utilized more for the management of SCI due to higher safety and more efficient delivery of therapeutic substances to recipient cells relative to MSCs. Their research data suggested that HucMSCs-EVs improved neurological recovery post SCI by carrying miR-26b-5p to target the intracellular KDM6A/NOX4 axis, and the effect was enhanced after overexpression of miR-26b-5p in HucMSCs-Evs [ 80 ]. However, systemically injected exosomes undergo rapid clearance, which harms microenvironment regulation and limits the regenerative outcomes [ 81 ].…”